Systemic therapy options following first-line chemoimmunotherapy in small-cell lung cancer

Nearly all patients with extensive-stage small-cell lung cancer (ES-SCLC) relapse following first-line etoposide plus platinum (EP) with or without immune checkpoint inhibition. Topotecan and amrubicin are chemotherapies approved for these patients. The toxicities of these chemotherapies are signifi...

Descripción completa

Detalles Bibliográficos
Autor principal: Pacheco, Jose M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2020
Materias:
Review Article on Small Cell Lung Cancer
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7656348/
https://www.ncbi.nlm.nih.gov/pubmed/33209465
http://dx.doi.org/10.21037/jtd.2020.03.67

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7656348/
https://www.ncbi.nlm.nih.gov/pubmed/33209465
http://dx.doi.org/10.21037/jtd.2020.03.67

Ejemplares similares